274 related articles for article (PubMed ID: 21285888)
1. Treatment monitoring in gliomas: comparison of dynamic susceptibility-weighted contrast-enhanced and spectroscopic MRI techniques for identifying treatment failure.
Vöglein J; Tüttenberg J; Weimer M; Gerigk L; Kauczor HU; Essig M; Weber MA
Invest Radiol; 2011 Jun; 46(6):390-400. PubMed ID: 21285888
[TBL] [Abstract][Full Text] [Related]
2. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M
Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706
[TBL] [Abstract][Full Text] [Related]
3. Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease.
Seeger A; Braun C; Skardelly M; Paulsen F; Schittenhelm J; Ernemann U; Bisdas S
Acad Radiol; 2013 Dec; 20(12):1557-65. PubMed ID: 24200483
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of proton magnetic resonance spectroscopy and perfusion-weighted imaging in brain gliomas follow-up: a single institutional experience.
Anselmi M; Catalucci A; Felli V; Vellucci V; Di Sibio A; Gravina GL; Di Staso M; Di Cesare E; Masciocchi C
Neuroradiol J; 2017 Jun; 30(3):240-252. PubMed ID: 28627984
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
[TBL] [Abstract][Full Text] [Related]
7. Partially resected gliomas: diagnostic performance of fluid-attenuated inversion recovery MR imaging for detection of progression.
Winterstein M; Münter MW; Burkholder I; Essig M; Kauczor HU; Weber MA
Radiology; 2010 Mar; 254(3):907-16. PubMed ID: 20177101
[TBL] [Abstract][Full Text] [Related]
8. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
[TBL] [Abstract][Full Text] [Related]
9. Comparison of unsupervised classification methods for brain tumor segmentation using multi-parametric MRI.
Sauwen N; Acou M; Van Cauter S; Sima DM; Veraart J; Maes F; Himmelreich U; Achten E; Van Huffel S
Neuroimage Clin; 2016; 12():753-764. PubMed ID: 27812502
[TBL] [Abstract][Full Text] [Related]
10. Dynamic susceptibility contrast and dynamic contrast-enhanced MRI characteristics to distinguish microcystic meningiomas from traditional Grade I meningiomas and high-grade gliomas.
Hussain NS; Moisi MD; Keogh B; McCullough BJ; Rostad S; Newell D; Gwinn R; Foltz G; Mayberg M; Aguedan B; Good V; Fouke SJ
J Neurosurg; 2017 Apr; 126(4):1220-1226. PubMed ID: 27285539
[TBL] [Abstract][Full Text] [Related]
11. [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].
Lichy MP; Bachert P; Hamprecht F; Weber MA; Debus J; Schulz-Ertner D; Schlemmer HP; Kauczor HU
Rofo; 2006 Jun; 178(6):627-33. PubMed ID: 16703499
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values.
Senft C; Hattingen E; Pilatus U; Franz K; Schänzer A; Lanfermann H; Seifert V; Gasser T
Neurosurgery; 2009 Nov; 65(5):908-13; discussion 913. PubMed ID: 19834403
[TBL] [Abstract][Full Text] [Related]
13. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging.
Law M; Cha S; Knopp EA; Johnson G; Arnett J; Litt AW
Radiology; 2002 Mar; 222(3):715-21. PubMed ID: 11867790
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of quantitative peritumoural perfusion and proton spectroscopic magnetic resonance imaging evaluation in differentiating brain gliomas from solitary brain metastases.
Sparacia G; Gadde JA; Iaia A; Sparacia B; Midiri M
Neuroradiol J; 2016 Jun; 29(3):160-7. PubMed ID: 26988081
[TBL] [Abstract][Full Text] [Related]
15. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
Thomsen H; Steffensen E; Larsson EM
Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
[TBL] [Abstract][Full Text] [Related]
16. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response.
Law M; Oh S; Babb JS; Wang E; Inglese M; Zagzag D; Knopp EA; Johnson G
Radiology; 2006 Feb; 238(2):658-67. PubMed ID: 16396838
[TBL] [Abstract][Full Text] [Related]
17. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
[TBL] [Abstract][Full Text] [Related]
18. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.
Pirzkall A; Li X; Oh J; Chang S; Berger MS; Larson DA; Verhey LJ; Dillon WP; Nelson SJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):126-37. PubMed ID: 15093908
[TBL] [Abstract][Full Text] [Related]
19. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI.
Fayed N; Dávila J; Medrano J; Olmos S
Eur J Radiol; 2008 Sep; 67(3):427-33. PubMed ID: 18442889
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
Liao W; Liu Y; Wang X; Jiang X; Tang B; Fang J; Chen C; Hu Z
Acta Radiol; 2009 Mar; 50(2):217-25. PubMed ID: 19096950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
